Pre-made Visilizumab benchmark antibody ( Whole mAb, anti-CD3E therapeutic antibody, Anti-T3E/TCRE/IMD18/CD3epsilon Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Visilizumab biosimilar, Whole mAb, Anti-CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Visilizumab (tentative trade name Nuvion, PDL BioPharma Inc.) is a humanized monoclonal antibody. It is being investigated for use as an immunosuppressive drug in patients with ulcerative colitis and Crohn’s disease. Visilizumab binds to the CD3 receptor on certain activated T cells without affecting resting T cells. It is currently under clinical studies for the treatment of ulcerative colitis and Crohn’s disease.
| Products Name (INN Index) | Pre-Made Visilizumab biosimilar, Whole mAb, Anti-CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody |
|---|---|
| INN Name | Visilizumab |
| Target | CD3E |
| Format | Whole mAb |
| Derivation | NA |
| Species Reactivity | Human |
| CH1 Isotype | IgG2 |
| VD LC | nd |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2000 |
| Year Recommended | 2001 |
| Companies | PDL BioPharma |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Crohn's disease,Graft-versus-host disease,Psoriasis,Renal transplant rejection,Ulcerative colitis |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | CD3E |
| Package |
